ARS Pharmaceuticals, Inc. reported $117M of revenue over the trailing twelve months, +4.1% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $117M (to Q2 2026). Net income: −$215M, trailing twelve months to Q2 2026. Free cash flow: −$197M, trailing twelve months to Q2 2026. Operating margin: −190%, trailing twelve months to Q2 2026.

SPRYARS Pharmaceuticals, Inc.

Healthcare

$4.57-56% 1Y

$4.57

$4.0752 weeks$13.06

SPRY as reported

ARS Pharmaceuticals, Inc. reported $117M of revenue over the trailing twelve months, +4.1% on the year before. 9 reported series are charted on this page, each one as filed.

$117M

Revenue, trailing twelve months · to Q2 2026 · +4.1% against the twelve months before

Net income: −$215M
Net income · +349% year on year · trailing twelve months to Q2 2026
Free cash flow: −$197M
Free cash flow · +268% year on year · trailing twelve months to Q2 2026
Operating margin: −190%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for SPRY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$117M	+4.1%	Q2 2026
Net income	−$215M	+349%	Q2 2026
EPS	−$2.18	+336%	Q2 2026
Operating margin	−190%	n/a	Q2 2026
Net margin	−189%	n/a	Q2 2026
ROE	−562%	n/a	Q2 2026
ROA	−57%	n/a	Q2 2026
ROIC	360%	n/a	Q2 2026
Free cash flow	−$197M	+268%	Q2 2026

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.